Ligand id: 6881

Name: tocilizumab

IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: tocilizumab

Immunopharmacology Comments
Tocilizumab neutralises circulating IL-6, thereby reducing IL-6R activation, which in turn leads to a reduction in cytokine and acute phase reactant production, and eventual symptomatic relief.
Immunopharmacology Disease
Disease X-Refs Comment References
Temporal arteritis Disease Ontology: DOID:13375
OMIM: 187360
Orphanet: ORPHA397
Approved drug for temporal (giant cell) arteritis (May 2017).
Juvenile idiopathic arthritis- systemic OMIM: 604302
An anti-IL-6 therapy approved for sJIA.
Rheumatoid arthritis Disease Ontology: DOID:7148
OMIM: 180300
Tocilizumab was the first humanized mAb to be developed against the human the IL-6 receptor, and is now an approved therapeutic for RA.